Marcus Lind

List of Publications by Year
in descending order

97 papers	5,078 citations	126907 33 h-index	95266 68 g-index
98 all docs	98 docs citations	98 times ranked	6618 citing authors

#	Article	IF	Citations
1	Excess Mortality among Persons with Type 2 Diabetes. New England Journal of Medicine, 2015, 373, 1720-1732.	27.0	777
2	Glycemic Control and Excess Mortality in Type 1 Diabetes. New England Journal of Medicine, 2014, 371, 1972-1982.	27.0	717
3	Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections. JAMA - Journal of the American Medical Association, 2017, 317, 379.	7.4	520
4	Glycaemic control and incidence of heart failure in 20â€˜985 patients with type 1 diabetes: an observational study. Lancet, The, 2011, 378, 140-146.	13.7	222
5	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the) Tj ETQq1 1 0.784314 rgBT /Overlock	8.6	190
6	A Clinical Trial of the Accuracy and Treatment Experience of the Flash Glucose Monitor FreeStyle Libre in Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2017, 19, 164-172.	4.4	143
7	Mortality trends in patients with and without diabetes in Ontario, Canada and the UK from 1996 to 2009: a population-based study. Diabetologia, 2013, 56, 2601-2608.	6.3	142
8	HbA$_{1c}$ level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study. BMJ: British Medical Journal, 2019, 366, l4894.	2.3	109
9	A Randomized Clinical Trial of the Effect of Continuous Glucose Monitoring on Nocturnal Hypoglycemia, Daytime Hypoglycemia, Glycemic Variability, and Hypoglycemia Confidence in Persons with Type 1 Diabetes Treated with Multiple Daily Insulin Injections (GOLD-3). Diabetes Technology and Therapeutics, 2018, 20, 274-284.	4.4	88
10	The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes. Diabetologia, 2012, 55, 2946-2953.	6.3	84
11	A Clinical Trial of the Accuracy and Treatment Experience of the Dexcom G4 Sensor (Dexcom G4) Tj ETQq1 1 0.784314 rgBT /Overlock with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2014, 16, 759-767.	4.4	76
12	The shape of the metabolic memory of HbA1c: re-analysing the DCCT with respect to time-dependent effects. Diabetologia, 2010, 53, 1093-1098.	6.3	75
13	Adherence of self-monitoring of blood glucose in persons with type 1 diabetes in Sweden. BMJ Open Diabetes Research and Care, 2017, 5, e000342.	2.8	70
14	Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study. Cardiovascular Diabetology, 2020, 19, 9.	6.8	70
15	Long-term excess risk of heart failure in people with type 1 diabetes: a prospective case-control study. Lancet Diabetes and Endocrinology,the, 2015, 3, 876-885.	11.4	69
16	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. Journal of Diabetes Science and Technology, 2023, 17, 1226-1242.	2.2	69
17	Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. Thrombosis Research, 2012, 129, 32-35.	1.7	65
18	Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Primary Care Diabetes, 2012, 6, 41-46.	1.8	65

#	Article	IF	Citations
19	The True Value of HbA1c as a Predictor of Diabetic Complications: Simulations of HbA1c Variables. PLoS ONE, 2009, 4, e4412.	2.5	61
20	Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). BMJ, The, 2015, 351, h5364.	6.0	53
21	Risk of atrial fibrillation in people with type 1 diabetes compared with matched controls from the general population: a prospective case-control study. Lancet Diabetes and Endocrinology,the, 2017, 5, 799-807.	11.4	53
22	Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88. Diabetes Care, 2021, 44, 2231-2237.	8.6	51
23	Age at diagnosis predicts deterioration in glycaemic control among children and adolescents with type 1 diabetes. BMJ Open Diabetes Research and Care, 2014, 2, e000039.	2.8	48
24	BMI, Mortality, and Cardiovascular Outcomes in Type 1 Diabetes: Findings Against an Obesity Paradox. Diabetes Care, 2019, 42, 1297-1304.	8.6	47
25	A systematic review of HbA1c variables used in the study of diabetic complications. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2008, 2, 282-293.	3.6	45
26	Glycaemic control and excess risk of major coronary events in persons with type 1 diabetes. Heart, 2017, 103, 1687-1695.	2.9	41
27	Use of fastâ€acting insulin aspart in insulin pump therapy in clinical practice. Diabetes, Obesity and Metabolism, 2019, 21, 2039-2047.	4.4	41
28	Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2. Diabetes Care, 2019, 42, 1081-1087.	8.6	40
29	Relationship Between Overweight and Obesity With Hospitalization for Heart Failure in 20,985 Patients With Type 1 Diabetes. Diabetes Care, 2013, 36, 2857-2861.	8.6	39
30	Longâ€term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the <scp>DEPICT</scp>â€2 study): 52â€week results from a randomized controlled trial. Diabetes, Obesity and Metabolism, 2020, 22, 1516-1526.	4.4	38
31	The Association between HbA1c, Fasting Glucose, 1-Hour Glucose and 2-Hour Glucose during an Oral Glucose Tolerance Test and Cardiovascular Disease in Individuals with Elevated Risk for Diabetes. PLoS ONE, 2014, 9, e109506.	2.5	38
32	Glycemic Control and Excess Mortality in Type 1 Diabetes. New England Journal of Medicine, 2015, 372, 879-881.	27.0	36
33	The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: An observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. Primary Care Diabetes, 2012, 6, 53-59.	1.8	35
34	The Association Between HbA1c and Time in Hypoglycemia During CGM and Self-Monitoring of Blood Glucose in People With Type 1 Diabetes and Multiple Daily Insulin Injections: A Randomized Clinical Trial (GOLD-4). Diabetes Care, 2020, 43, 2017-2024.	8.6	34
35	Insulin Pumpâ€"Long-Term Effects on Glycemic Control: An Observational Study at 10 Diabetes Clinics in Sweden. Diabetes Technology and Therapeutics, 2013, 15, 302-307.	4.4	32
36	Incidence and risk factors for mortality and end-stage renal disease in people with type 2 diabetes and diabetic kidney disease: a population-based cohort study in the UK. BMJ Open Diabetes Research and Care, 2021, 9, e002146.	2.8	32

#	Article	IF	Citations
37	Excess risk of hospitalisation for heart failure among people with type 2 diabetes. Diabetologia, 2018, 61, 2300-2309.	6.3	31
38	BMI and Mortality in Patients With New-Onset Type 2 Diabetes: A Comparison With Age- and Sex-Matched Control Subjects From the General Population. Diabetes Care, 2018, 41, 485-493.	8.6	29
39	Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial. Diabetes Care, 2021, 44, 1604-1612.	8.6	27
40	The association between <scp>BMI</scp> and hospitalization for heart failure in 83Â021 persons with TypeÂ2 diabetes: a populationâ€based study from the Swedish National Diabetes Registry. Diabetic Medicine, 2014, 31, 586-594.	2.3	25
41	Predicting the Effectiveness of Insulin Pump Therapy on Glycemic Control in Clinical Practice: A Retrospective Study of Patients with Type 1 Diabetes from 10 Outpatient Diabetes Clinics in Sweden over 5 Years. Diabetes Technology and Therapeutics, 2015, 17, 21-28.	4.4	23
42	Assessing the Accuracy of Continuous Glucose Monitoring (CGM) Calibrated With Capillary Values Using Capillary or Venous Glucose Levels as a Reference. Journal of Diabetes Science and Technology, 2016, 10, 876-884.	2.2	23
43	<scp>Longâ€term</scp> efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled <scp>52â€week</scp> outcomes from the <scp>DEPICT</scp>â€1 and â€2 studies. Diabetes, Obesity and Metabolism, 2021, 23, 549-560.	4.4	21
44	Glycaemic control and excess risk of ischaemic and haemorrhagic stroke in patients with type 1 diabetes: a cohort study of 33 453 patients. Journal of Internal Medicine, 2017, 281, 261-272.	6.0	19
45	Impact of chronic kidney disease definition on assessment of its incidence and risk factors in patients with newly diagnosed type 1 and type 2 diabetes in the UK: A cohort study using primary care data from the United Kingdom. Primary Care Diabetes, 2020, 14, 381-387.	1.8	19
46	Impact of CKD Progression on Cardiovascular Disease Risk in a Contemporary UK Cohort of Individuals With Diabetes. Kidney International Reports, 2020, 5, 1651-1660.	0.8	19
47	Sustained Intensive Treatment and Long-term Effects on HbA1c Reduction (SILVER Study) by CGM in People With Type 1 Diabetes Treated With MDI. Diabetes Care, 2021, 44, 141-149.	8.6	19
48	Estimated glucose disposal rate and risk of stroke and mortality in type 2 diabetes: a nationwide cohort study. Cardiovascular Diabetology, 2021, 20, 202.	6.8	19
49	Design and Methods of a Randomized Trial of Continuous Glucose Monitoring in Persons With Type 1 Diabetes With Impaired Glycemic Control Treated With Multiple Daily Insulin Injections (GOLD Study). Journal of Diabetes Science and Technology, 2016, 10, 754-761.	2.2	18
50	Risk factors for diabetic retinopathy in people with Type 2 diabetes: A caseâ€“control study in a UK primary care setting. Primary Care Diabetes, 2016, 10, 300-308.	1.8	18
51	Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3). BMJ Open Diabetes Research and Care, 2018, 6, e000464.	2.8	18
52	The relationship between three eGFR formulas and hospitalization for heart failure in 54Â486 individuals with type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2016, 32, 730-735.	4.0	17
53	Excess risk of lower extremity amputations in people with type 1 diabetes compared with the general population: amputations and type 1 diabetes. BMJ Open Diabetes Research and Care, 2019, 7, e000602.	2.8	17
54	Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial). Primary Care Diabetes, 2015, 9, 15-22.	1.8	16

#	Article	IF	Citations
55	Recognition of Incident Diabetes Mellitus During an Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 260-267.	2.2	16
56	Long‐term excess risk of stroke in people with Type 2 diabetes in Sweden according to blood pressure level: a population‐based case–control study. Diabetic Medicine, 2017, 34, 522-530.	2.3	16
57	Risk Factors for Atrial Fibrillation in People With Type 1 Diabetes: An Observational Cohort Study of 36,258 Patients From the Swedish National Diabetes Registry. Diabetes Care, 2019, 42, 1530-1538.	8.6	16
58	Effect on Glycemic Control by Short- and Long-Term Use of Continuous Glucose Monitoring in Clinical Practice. Journal of Diabetes Science and Technology, 2011, 5, 1472-1479.	2.2	15
59	Incretin therapy and its effect on body weight in patients with diabetes. Primary Care Diabetes, 2012, 6, 187-191.	1.8	15
60	Changes in HbA1c and frequency of measuring HbA1c and adjusting glucose-lowering medications in the 10 years following diagnosis of type 2 diabetes: a population-based study in the UK. Diabetologia, 2014, 57, 1586-1594.	6.3	15
61	Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy. American Heart Journal, 2016, 182, 111-118.	2.7	15
62	Effect of Liraglutide on Times in Glycaemic Ranges as Assessed by CGM for Type 2 Diabetes Patients Treated With Multiple Daily Insulin Injections. Diabetes Therapy, 2019, 10, 2115-2130.	2.5	15
63	Evaluation of Reference Metrics for Continuous Glucose Monitoring in Persons Without Diabetes and Prediabetes. Journal of Diabetes Science and Technology, 2022, 16, 373-382.	2.2	15
64	Glycemic Control, Renal Complications, and Current Smoking in Relation to Excess Risk of Mortality in Persons With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2016, 10, 1006-1014.	2.2	14
65	Trajectories in HbA1c and other risk factors among adults with type 1 diabetes by age at onset. BMJ Open Diabetes Research and Care, 2021, 9, e002187.	2.8	13
66	Risk factors and incidence over time for lower extremity amputations in people with type 1 diabetes: an observational cohort study of 46,088 patients from the Swedish National Diabetes Registry. Diabetologia, 2021, 64, 2751-2761.	6.3	13
67	Availability of insulin pump therapy in clinical practice. Diabetic Medicine, 2012, 29, 1055-1059.	2.3	12
68	Decreased eGFR as a Risk Factor for Heart Failure in 13 781 Individuals With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2016, 10, 131-136.	2.2	12
69	Prevalence of primary aldosteronism among patients with type 2 diabetes. Clinical Endocrinology, 2017, 87, 233-241.	2.4	12
70	Contrasting Associations of Body Mass Index and Hemoglobin A1c on the Excess Risk of Acute Myocardial Infarction and Heart Failure in Type 2 Diabetes Mellitus. Journal of the American Heart Association, 2019, 8, e013871.	3.7	12
71	Predictors and correlates of systolic blood pressure reduction with liraglutide treatment in patients with type 2 diabetes. Journal of Clinical Hypertension, 2019, 21, 105-115.	2.0	12
72	Body mass index as a risk factor for coronary events and mortality in patients with type 1 diabetes. Open Heart, 2018, 5, e000727.	2.3	11

#	Article	IF	Citations
73	Effects of nutrition education using a food-based approach, carbohydrate counting or routine care in type 1 diabetes: 12 months prospective randomized trial. BMJ Open Diabetes Research and Care, 2021, 9, e001971.	2.8	11
74	Contemporary Risk Estimates of Three HbA1c Variables for Myocardial Infarction in 101,799 Patients Following Diagnosis of Type 2 Diabetes. Diabetes Care, 2015, 38, 1481-1486.	8.6	10
75	LDL cholesterol level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes mellitus: A nationwide cohort study. Journal of Internal Medicine, 2021, 289, 873-886.	6.0	10
76	Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2644-2651.	3.6	10
77	The Effect of Insulin Lispro on Glycemic Control in a Large Patient Cohort. Diabetes Technology and Therapeutics, 2009, 11, 51-56.	4.4	9
78	The majority of people with type <scp>1</scp> diabetes and multiple daily insulin injections benefit from using continuous glucose monitoring: An analysis based on the <scp>GOLD</scp> randomized trial (<scp>GOLD‐5</scp>). Diabetes, Obesity and Metabolism, 2021, 23, 619-630.	4.4	9
79	Contemporary risk estimates of three HbA1cvariables in relation to heart failure following diagnosis of type 2 diabetes. Heart, 2017, 103, 353-358.	2.9	8
80	Risk factors for diabetic macular oedema in type 2 diabetes: A case-control study in a United Kingdom primary care setting. Primary Care Diabetes, 2017, 11, 288-296.	1.8	8
81	Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI‐liraglutide study 5). Obesity Science and Practice, 2019, 5, 130-140.	1.9	8
82	Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden. Diabetes Therapy, 2016, 7, 321-333.	2.5	7
83	Glycemic Control and Risk of Sepsis and Subsequent Mortality in Type 2 Diabetes. Diabetes Care, 2022, 45, 127-133.	8.6	7
84	Prevalence and impact of chronic dysglycemia in intensive care unit patients—A retrospective cohort study. Acta Anaesthesiologica Scandinavica, 2021, 65, 82-91.	1.6	6
85	Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial. Diabetes Care, 2019, 42, 1464-1472.	8.6	5
86	Glycaemic control and excess risk of major coronary events in patients with type 2 diabetes: a population-based study. Open Heart, 2019, 6, e000967.	2.3	5
87	Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52‰weeks as add‐on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, Phase 3 trial. Diabetes, Obesity and Metabolism, 2020, 22, 957-968.	4.4	4
88	Characteristics of Continuous Glucose Monitoring Metrics in Persons with Type 1 and Type 2 Diabetes Treated with Multiple Daily Insulin Injections. Diabetes Technology and Therapeutics, 2021, 23, 425-433.	4.4	3
89	Renal Complications and Duration of Diabetes: An International Comparison in Persons with Type 1 Diabetes. Diabetes Therapy, 2021, 12, 3093-3105.	2.5	3
90	Risk factors for nephropathy in persons with type 1 diabetes: a population-based study. Acta Diabetologica, 2022, , 1.	2.5	3

#	Article	IF	Citations
91	Glycated Hemoglobin A1c Levels in Type 1 Diabetes Mellitus and Outcomes After Myocardial Infarction. Circulation, 2019, 139, 2380-2382.	1.6	2
92	Early and long-term prognosis in patients with and without type 2 diabetes after carotid intervention: a Swedish nationwide propensity score matched cohort study. Cardiovascular Diabetology, 2021, 20, 85.	6.8	2
93	Evaluation of Effects of Continuous Glucose Monitoring on Physical Activity Habits and Blood Lipid Levels in Persons With Type 1 Diabetes Managed With Multiple Daily Insulin Injections: An Analysis Based on the GOLD Randomized Trial (GOLD 8). Journal of Diabetes Science and Technology, 2024, 18, 89-98.	2.2	2
94	Effect of liraglutide on markers of insulin production in persons with type 2 diabetes treated with multiple daily insulin injections. Journal of Diabetes and Its Complications, 2022, 36, 108110.	2.3	1
95	Atrial fibrillation and type 1 diabetes – Authors' reply. Lancet Diabetes and Endocrinology,the, 2017, 5, 937.	11.4	0
96	Investigation of early signs of systolic and diastolic dysfunction among persons with type 1 diabetes. Open Heart, 2019, 6, e001020.	2.3	0
97	Variables associated with insulin production in persons with type 2 diabetes treated with multiple daily insulin injections. Primary Care Diabetes, 2021, 15, 607-613.	1.8	0